Previous 10 | Next 10 |
home / stock / bnigf / bnigf news
Sydney, Australia (ABN Newswire) - Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based biopharmaceutical enterprise, announced the latest clinical study of its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) demonstrated an overall sensitivity of 95% and specificity of 100%...
NEW YORK and SYDNEY, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise, announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug development company,...
Beroni Group (BNIGF) announces that it has signed a Memorandum of Understanding ((MOU)) with tella to collaborate in the field of immunotherapy for cancer treatment.Beroni is an Australia-based diversified biopharmaceutical enterprise, while tella is a Japanese company conducti...
NEW YORK and SYDNEY, Australia, May 28, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise today announced that it has signed a Memorandum of Understanding with t...
NEW YORK and SYDNEY, Australia, May 28, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise today announced that it has raised US$2 million via the issue of conver...
Sydney, Australia (ABN Newswire) - Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based diversified biopharmaceutical enterprise today announced that it has signed a Memorandum of Understanding with tella, Inc. to collaborate in the field of immunotherapy for cancer treatment. tella i...
Sydney, Australia (ABN Newswire) - Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based diversified biopharmaceutical enterprise today announced that it has received the notification that its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) is granted authorization for export. As...
NEW YORK and SYDNEY, Australia, April 27, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise today announced that it has received the notification that its SARS...
Sydney, Australia (ABN Newswire) - Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that it...
Sydney, Australia (ABN Newswire) - Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based diversified biopharmaceutical enterprise today announces that it has completed its majority acquisition of the Sydney-based anticancer drug development company, PENAO Pty Ltd. As a result of this acq...
News, Short Squeeze, Breakout and More Instantly...
Sydney, Australia (ABN Newswire) - Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG) advises that it has entered into an unsecured and interest free convertible loan agreement with a group of investors for a principal loan amount of US$410,397. The loan is convertible at US$1.00 per share (post-...
Sydney, Australia (ABN Newswire) - Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG) advises that it has entered into an unsecured and interest free convertible loan agreement with an investor for a principal loan amount of US$205,679. The loan is convertible at US$1.00 per share upon listing of the...
Sydney, Australia (ABN Newswire) - Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG) advises that it has entered into unsecured and interest free convertible loan agreements with two investors for an aggregate principal loan amount of US$291,545. The loan is convertible at US$1.50 per share upon...